M2’s Scientists to Leverage PerkinElmer’s Robotic Cellular Screening Workstations for Insights into Materials and BioMedical Sciences

WHAT: PerkinElmer, Inc. a global leader committed to innovating for a healthier world, today announced that researchers at Australia’s new M2 medtech R&D initiative will utilize its cell::explorer™ robotic workstations for cell cultivation and phenotypic screening.

WHEN & WHERE: Australia’s Minister for Industry, Innovation and Science; Senator Arthur Sinodinos AO, officially launched M2 today in Clayton, Melbourne. He was joined by CSIRO’s Chief Scientist, Anita Hill, and Monash University’s Provost and Senior Vice-President, Professor Marc Parlange.

WHO: M2 is a collaboration between Monash University and Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO) to accelerate research, discovery and commercialization in Australia’s growing medical technology landscape.

WHY: M2 transitions medical technologies from the bench to scale-up, prototyping, pre-clinical testing, industry evaluation and adoption. It will help Australian medtech companies develop new, world first biomedical materials and technologies.

PerkinElmer’s cell::explorer™ robotic work stations will analyze and manipulate these biomedical materials while providing downstream high throughput screening, so that researchers can gain insights into how complex compounds affect cells.

The cell::explorer™ has been installed at CSIRO’s contribution to M2, the Biomedical Materials Translational Facility (BMTF). Among the projects it will assist with are ones developing a new synthetic heart valve and stent that could drastically cut the need for medical intervention or ongoing, postsurgery medication.

MORE: “This new facility represents a major collaborative effort to enhance Australia’s global position in the medical technology landscape,” said Veronica Glattauer, the CSIRO Cell Material Interactions team leader in charge of M2’s cell::explorer™ system.

“As we develop a wide range of biomedical materials, PerkinElmer’s automated robotic platform will be used to assess how novel materials in future products affect cells and tissues”. “PerkinElmer is excited to deliver our robotic workstations to M2 and to help accelerate their research in materials and biomedical sciences,” said Masoud Toloue, Vice President, Applied Genomics, PerkinElmer.

MORE: PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.